Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.

Melissa L. Johnson, Himisha Beltran, Hirva Mamdani et al.|Journal of Clinical Oncology|2022

Cited by 45